Predicting the response to intravenous immunoglobulins in an animal model of chronic neuritis

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disabling autoimmune disorder of the peripheral nervous system (PNS). Intravenous immunoglobulins (IVIg) are effective in CIDP, but the treatment response varies greatly between individual patients. Understanding this interindivid...

Full description

Saved in:
Bibliographic Details
Main Authors: Meyer zu Hörste, Gerd (Author) , Pfaff, Johannes (Author) , Bendszus, Martin (Author) , Pham, Mirko (Author)
Format: Article (Journal)
Language:English
Published: 6 October 2016
In: PLOS ONE
Year: 2016, Volume: 11, Issue: 10
ISSN:1932-6203
DOI:10.1371/journal.pone.0164099
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1371/journal.pone.0164099
Verlag, kostenfrei, Volltext: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164099
Get full text
Author Notes:Gerd Meyer zu Horste, Steffen Cordes, Johannes Pfaff, Christian Mathys, Anne K. Mausberg, Martin Bendszus, Mirko Pham, Hans-Peter Hartung, Bernd C. Kieseier
Description
Summary:Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disabling autoimmune disorder of the peripheral nervous system (PNS). Intravenous immunoglobulins (IVIg) are effective in CIDP, but the treatment response varies greatly between individual patients. Understanding this interindividual variability and predicting the response to IVIg constitute major clinical challenges in CIDP. We previously established intercellular adhesion molecule (ICAM)-1 deficient non-obese diabetic (NOD) mice as a novel animal model of CIDP. Here, we demonstrate that similar to human CIDP patients, ICAM-1 deficient NOD mice respond to IVIg treatment by clinical and histological measures. Nerve magnetic resonance imaging and histology demonstrated that IVIg ameliorates abnormalities preferentially in distal parts of the sciatic nerve branches. The IVIg treatment response also featured great heterogeneity allowing us to identify IVIg responders and non-responders. An increased production of interleukin (IL)-17 positively predicted IVIg treatment responses. In human sural nerve biopsy sections, high numbers of IL-17 producing cells were associated with younger age and shorter disease duration. Thus, our novel animal model can be utilized to identify prognostic markers of treatment responses in chronic inflammatory neuropathies and we identify IL-17 production as one potential such prognostic marker.
Item Description:Gesehen am 07.11.2017
Physical Description:Online Resource
ISSN:1932-6203
DOI:10.1371/journal.pone.0164099